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ABSTRACT
Introduction: Gout is the most common inflammatory
arthritis in men over 40 years of age. Long-term urate-
lowering therapy is considered a key strategy for
effective gout management. The primary outcome
measure for efficacy in clinical trials of urate-lowering
therapy is serum urate levels, effectively acting as a
surrogate for patient-centred outcomes such as
frequency of gout attacks or pain. Yet it is not clearly
demonstrated that the strength of the relationship
between serum urate and clinically relevant outcomes
is sufficiently strong for serum urate to be considered
an adequate surrogate. Our objective is to investigate
the strength of the relationship between changes in
serum urate in randomised controlled trials and
changes in clinically relevant outcomes according to
the ‘Biomarker-Surrogacy Evaluation Schema version 3’
(BSES3), documenting the validity of selected
instruments by applying the ‘OMERACT Filter 2.0’.
Methods and analysis: A systematic review
described in terms of the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
reporting guidelines will identify all relevant studies.
Standardised data elements will be extracted from each
study by 2 independent reviewers and disagreements
are resolved by discussion. The data will be analysed
by meta-regression of the between-arm differences in
the change in serum urate level (independent variable)
from baseline to 3 months (or 6 and 12 months if
3-month values are not available) against flare rate,
tophus size and number and pain at the final study
visit (dependent variables).
Ethics and dissemination: This study will not
require specific ethics approval since it is based on
analysis of published (aggregated) data. The intended
audience will include healthcare researchers,
policymakers and clinicians. Results of the study will
be disseminated by peer-reviewed publications.
Trial registration number: CRD42016026991.
INTRODUCTION
Clinicians making treatment decisions
should refer to methodologically strong clin-
ical trials examining the impact of therapy
on clinically important outcomes (ie, out-
comes that are important to patients).
However, clinically important outcomes can
be difﬁcult to study, as the required trials
need very large sample sizes or long-term
patient follow-up. Thus researchers or drug
developers look for alternatives. Substituting
surrogate end points for the target event
allows conduct of shorter and smaller trials,
thus offering a solution to the dilemma, if
the end points are convincing as surrogate
end points.
There are obvious advantages to using bio-
markers and surrogate end points, but con-
cerns about clinical applicability and
statistical validity to evaluate these aspects
hinder their efﬁcient application. A surro-
gate end point may be deﬁned as an ‘object-
ive’ laboratory measurement or a physical
sign used as a substitute for a clinically mean-
ingful end point that measures directly how a
patient feels, functions or survives.1 This def-
inition was recommended and further
explored at a National Institute of Health
(NIH) sponsored workshop in 1998 which
agreed on deﬁnitions for biomarker,
Strengths and limitations of this study
▪ Our study’s strengths include clinical expertise in
rheumatology.
▪ The content experts in the group have extensive
knowledge of the literature and experience with
gout treatment.
▪ The methodologists in the group are members
of the Outcome Measures in Rheumatology
Clinical Trials (OMERACT) Gout Working Group,
and have experience with conducting and report-
ing randomised clinical trials, systematic reviews
and meta-analyses.
▪ A possible and anticipated weakness may be the
quantity and quality of the trials we identify.
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surrogate end point and clinical end point. The agreed
deﬁnition of a biomarker states ‘a biological marker
(biomarker) is a characteristic that is objectively mea-
sured and evaluated as an indicator of normal biologic
processes, pathogenic processes or pharmacologic
responses to a therapeutic intervention’.2 3
In gout, monosodium crystal formation occurs when
supersaturation levels of ∼6.8 mg/dL (0.41 mmol/L) are
reached at 37°C. Reduction in serum urate (SU) to
<6 mg/dL (0.36 mmol/L) is a key goal in the long-term
management of gout. As such SU measurement has
become an integral part of the management of
gout and a critical outcome measure in clinical
studies of gout therapies. The Outcome Measures in
Rheumatology Clinical Trials (OMERACT) Delphi exer-
cise identiﬁed SU as a mandatory outcome measure in
chronic gout studies with the highest median rating.4 SU
as a biomarker makes inherent sense given the strong
relationship between the risk of gout and SU. However,
is SU a surrogate end point of relevant clinical outcomes
such as gout attacks, tophus regression and radiological
damage?
Background
At OMERACT 8 (Malta, 2006) Lassere et al5 proposed a
schema for the evaluation of biomarkers as surrogate
end points. The schema was operationalised as a score
obtained from four domains: target outcome, study
design, statistical strength and penalties.5 This schema
was based on the NIH deﬁnitions of biomarker, surro-
gate end point and clinical end point published in
2001.2 The distinction between a surrogate and a bio-
marker was determined by the strength of association
between the biomarker and the clinical end point of
interest. To be called a surrogate, it was proposed that a
biomarker must meet the rank (score) of at least three
within the target outcome, study design and statistical
strength domains, and there must not be evidence from
a randomised controlled trial (RCT) that the use of the
biomarker caused patient harm.5
At OMERACT 9 (Kananaskis, 2008) the soluble bio-
marker group revised the requirements for the speciﬁc
situation of a soluble biomarker being predictive of
structural radiographic damage in ankylosing spondyl-
itis, psoriatic arthritis and rheumatoid arthritis.6 There
was an increased emphasis on the technical assay
requirements of the biomarker but the strength of asso-
ciation domain, while discussed in the text, did not
appear in the OMERACT 9 levels of evidence frame-
work. There was no consensus on all aspects of the
framework, and the criteria by which a soluble bio-
marker could be said to meet the levels of evidence
framework were not deﬁned.
At OMERACT 10 (Kota Kinabalu, 2010) evidence was
presented that SU fulﬁlled the OMERACT 9 soluble bio-
marker requirements in terms of domain 4 (perform-
ance criteria) and there is limited evidence from
observational studies and one RCT that changes in SU
were associated with changes in patient-centred out-
comes for gout.7 However, the meeting did not endorse
SU as a biomarker for clinically relevant outcomes for
gout. The reasons for the lack of endorsement might be
that the strength of evidence was weak, the criteria for
endorsement are unclear and the chosen patient-
centred outcomes (particularly the number of ﬂares)
were not universally held to be clinically meaningful.
In parallel to OMERACT, Lassere et al5 systematically
reviewed the biomarker–surrogate literature and modi-
ﬁed the levels of evidence schema built on the
OMERACT 8 proposal which over time went through
three iterations (‘Biomarker-Surrogacy Evaluation
Schema version’ (BSES), BSES1 which was the
OMERACT 8 proposal,5 BSES2 which speciﬁed the stat-
istical criteria more precisely8 and BSES3 which replaced
the penalties domain with a combined clinical and
pharmacological generalisability domain). BSES3 con-
tains four domains: study design, target outcome, statis-
tical evaluation and generalisability. It also speciﬁed the
kind of statistical association required to justify the link
between the biomarker and the clinical end point being
sufﬁciently strong to consider the biomarker as a surro-
gate end point.9 10
In 2012 blood pressure was evaluated using the BSES3
and online material described its application and inter-
pretation.10 The BSES3 framework represents the cur-
rently best available approach to validating a biomarker
as a surrogate end point. We propose that this frame-
work be endorsed by OMERACT as the framework for
validation of biomarker–surrogates for rheumatology
clinical trials. It represents the logical extension of work
developed at OMERACT 8 and provides a clear pathway
by which a putative biomarker, soluble or otherwise, can
be evaluated, in contrast to the OMERACT 9 framework.
For example, Lassere et al10 have used trial-level data
and the BSES3 framework to convincingly show that dia-
stolic and systolic blood pressures are valid surrogate
end points for stroke risk reduction. In a recent
meta-regression, the approach has also been used to
evaluate progression-free survival (PFS) in metastatic
renal cell carcinoma.11
Rationale
We wish to use the example of SU as a soluble bio-
marker for the major clinical end point of acute gout
attacks, in the disease of gout. A minor clinical end
point would be tophus size change from baseline to
ﬁnal visit, the change in the number of tophi, and pain.
Other patient relevant end points included in the
OMERACT core set of outcomes for clinical trials in
patients with chronic gout will also be evaluated in
exploratory analyses: health-related quality of life
(HRQOL), patient global assessment of disease activity
and physical disability (activities limitation).
The justiﬁcation for choosing this biomarker and the
clinical end point of ﬂares as the major end point is
described as follows:
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▸ First, SU is recommended as a treatment target by
several guidelines for the management of gout.12–14 This
strongly implies (although it is not stated explicitly) that
changes in SU or achievement of a target level of SU will
be strongly associated with clinically relevant outcomes.
▸ Second, some regulatory bodies (eg, Food and Drug
Administration and European Medicines Agency) have
tended to assume that beneﬁcial drug effects on SU will
likely have beneﬁcial effects on clinical outcomes in
gout. National Institute for Health and Care Excellence
(NICE) recommended that febuxostat be available for
people who are intolerant of allopurinol or who have
contraindications to allopurinol.15 In other words,
although NICE did not see persuasive evidence for
improved clinical outcomes with the use of febuxostat, it
was sufﬁcient that the drug effectively lowered SU to
below 6 mg/dL.
▸ Third, we have previously shown that SU fulﬁls the tech-
nical performance criteria for a valid soluble biomarker
proposed at OMERACT 9.7 Flare (acute attack) of gout
is a key clinical manifestation of gout. It constitutes the
primary or only manifestation for several years until per-
sistent, tophaceous disease develops. In the expectation
that effective management strategies aim to prevent
chronic tophaceous disease from occurring it is justiﬁ-
able to focus on attacks as the clinically relevant end
point for the majority of people for gout. Although
gout attacks can vary in severity (often modiﬁed by
acute gout treatment), it is clear that every attack is asso-
ciated with some level of symptoms and disability. Gout
attacks therefore align with how a patient ‘feels or func-
tions’ and can be reasonably be identiﬁed as a clinically
relevant end point.1
However, we recognise that other clinical outcomes
are relevant and will evaluate these within the same
framework. This proposal ﬁts in the Filter 2.0 framework
by making explicit and quantifying the link between
Core Area domains of Pathophysiology Manifestations
(biomarker) and domains of Life Impact (ﬂare, pain,
HRQOL, tophus). This framework links disease-centred
variables of biological and pathological processes with
patient-centred variables of how a patient feels, functions
and survives as proposed at OMERACT 6.5
Objectives
There are two objectives:
1. To determine the strength of the relationship
between SU and patient-relevant outcomes, including
ﬂares, tophi, HRQOL, pain and function using
meta-regression of RCTs.
2. To evaluate whether SU is a surrogate end point for
clinically relevant outcomes in patients with gout as
deﬁned by the BSES3 framework.
Hypothesis
A reduction in SU will be associated with improvement
in clinically relevant patient-reported outcomes includ-
ing gout ﬂares and tophus size/number.
METHODS AND ANALYSIS
Protocol and registration
The protocol for the systematic review and
meta-regression analysis was prepared while planning
and documenting the review methods, guarding the
project team against arbitrary decision-making during
review conduct and to prompt global collaboration.16
Our protocol was prepared according to the recommen-
dations given in Preferred Reporting Items for
Systematic Reviews and Meta-Analysis Protocols
(PRISMA-P)16 and registered on PROSPERO
(CRD42016026991); this protocol and coming manu-
scripts will conform to the PRISMA guidelines for
reporting systematic reviews and meta-analyses.17
Eligibility criteria
The eligibility criteria for objective 1 is any RCT compar-
ing an active drug (alone or in combination) in patients
with gout with any control or placebo, with a minimum
duration of 3 months. The eligibility criteria for objective
2 are any RCT, controlled clinical trial or open-label trial
(OLT) comparing an (apparently) active drug (alone or
in combination) in patients with gout with any control
or placebo, with a minimum duration of 3 months and
longitudinal observational studies of gout with a
minimum duration of 3 months.
For both criteria, patients will be at least 18 years of
age and meeting the preliminary American College
of Rheumatology (ACR) criteria for acute arthritis of
primary gout18 or given a diagnosis of gout as described
by the authors.
Search and selection of trials
The following electronic databases will be searched:
PubMed, EMBASE, the Cochrane Library including the
Cochrane Central Register of Controlled Trials
(CENTRAL) and Cochrane Database of Systematic
Reviews (CDSR). The search will be limited to English
language studies in humans, but not limited by year of
publication. The reference lists from comprehensive
reviews and identiﬁed clinical trials are also manually
searched.
Results of the various searches will be reviewed inde-
pendently by two authors (LS and MBM). Titles and
abstracts will be reviewed and if further information is
required (to assess eligibility criteria), the full text will
be obtained. A record of reasons for excluding studies
will be kept enabling generation of a ﬁgure illustrating
the ﬂow of information through the different phases of
the systematic review continuing to meta-regression ana-
lysis. Disagreements will be resolved by an independent
third mediator (WT).
Data extraction
EndNote X7 software will be used to manage the
records retrieved from searches of electronic databases.
Results from hand searches will be tracked on a
Microsoft Excel spreadsheet. A customised data
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extraction form will be created in Microsoft Excel to
capture all the information available for each individual
trial.
The biomarker is deﬁned as the change in SU from
baseline to 3 months, or where 3-month values are not
available, the value at 6 months or 12 months (in order
of preference). This can be estimated if only baseline
and change is reported.
The clinical end points (dependent variables) are
deﬁned as follows:
▸ Major outcome: gout ﬂares;
▸ Minor outcomes: size of sentinel tophus (if size was
not measured, we will use number or presence/
absence in order of preference) and pain at ﬁnal
study visit.
Exploratory analyses: HRQOL (36-Item Short Form
Health Survey, SF-36), patient global assessment of
disease activity, and physical disability (activities limita-
tion; eg, Health Assesment Questionnaire (HAQ)).
Effect sizes for continuous end points will be recorded
as the standardised mean difference. If there is more
than one active treatment arm, analysis will treat this as
a separate study that is, substudy (see Meta-regression
analysis section). All variable values will be based on the
intention-to-treat population from each study whenever
possible.
Risk of bias in individual studies and judging the quality
of evidence
The RCTs will be assessed for methodological quality
(ie, internal validity) using the Cochrane Risk of Bias
tool.19 If at least one of the domains is rated as inad-
equate, the trial will be considered at high risk of bias. If
all domains are judged as low, the trial will be considered
at low risk of bias. Otherwise, the trial is considered as
having unclear risk of bias. Data extraction and
risk-of-bias assessment will be performed independently
by two reviewers; disagreements will be resolved by a third
reviewer. While interpreting the overall ﬁndings after the
meta-analysis, etc, Grading of Recommendations
Assessment, Development and Evaluation (GRADE) will
be used to rate the overall quality of the evidence based
on both the apparent risk of bias, publication bias, impre-
cision, inconsistency, indirectness and magnitude of
effect; that is, the GRADE ratings of very low-quality, low-
quality, moderate-quality or high-quality evidence per
outcome will reﬂect the extent to which we are conﬁdent
that the effect estimates are correct.20
Meta-regression analysis
To combine the individual study results, we will perform
meta-analyses using SAS software (PROC MIXED V.9. 3;
SAS Institute, Cary, North Carolina, USA), applying a
restricted maximum likelihood (REML) method to esti-
mate the between-study variance (ie, T2) and the com-
bined estimate of effect. We will estimate the anticipated
heterogeneity between trials with a standard (Cochran’s)
Q-test statistic, and we will evaluate this based on the I2
value, which is interpreted as the percentage of variabil-
ity in treatment effect estimates that is due to between
study heterogeneity rather than chance. Although our
meta-regression analysis is undertaken correctly from a
technical point of view, relations with averages of
patients’ characteristics can be potentially misleading.
Thus, following our systematic review, we will attempt to
get access to individual participant datasets investigating
patients’ characteristics; this will to some extent move us
away from looking at relations across trials, to inspection
of relations within trials.21
The primary purpose of this project is to evaluate
the surrogacy status of SU as a ‘predictor’ of gout
ﬂare rate reduction using meta-regression of RCTs.
Randomisation is essential for the causal surrogacy rela-
tionship; therefore, only RCTs will be included in the
main meta-regression analysis. Non-randomised study
designs will be summarised separately by meta-regression
to conﬁrm the consistency of association between the
biomarker and clinical end points in other contexts.
Cohort studies will be summarised as a narrative review.
The analyses of both randomised and non-randomised
studies contribute to the evaluation of SU within the
BSES3 framework.
Furthermore, in the meta-regression, the relationship
between SU and clinically relevant outcomes can be
undertaken using different outcome metrics. We will
deﬁne these as primary and secondary analyses. In the
primary analysis the dependent variable is a rate ratio
(ie, an incidence density ratio) comparing the ratio of
incidence rates of gout ﬂare events in active versus
control arms occurring at any given point in time; inci-
dence rate is the occurrence of an event over person-
time (ie, in this setting in person-months). The rate
ratio allows trials of different duration to be included in
the analysis. The independent variable is between arm
difference of within-arm change (on-trial SU from base-
line SU) of SU. Therefore, in a trial of 3 months dur-
ation, ﬂare rate over 3 months is the dependent variable
and change in SU over 3 months is the independent
variable.
In secondary analyses the dependent variable is risk
ratio reduction (RRR) of within trial gout ﬂare rate. The
relative ratio reduction (also called the risk ratio reduc-
tion) is the ﬂare risk in the control arm minus the ﬂare
risk in the active arm, divided by the ﬂare risk in the
control arm (this can also be calculated by 1- relative
risk (RR), where RR is the ﬂare risk in the active arm
divided by the ﬂare risk in the control arm). Therefore
the relative risk reduction (RRR) is the difference in
ﬂare risk in two arms (control-active), expressed as a
percentage of the risk of the control arm.
The independent variable is within trial, by-arm differ-
ence of proportion with SU<6 mg/dL at the end of the
trial.
In a RCT, by-arm difference in SU change is likely to
be causal and change in SU is easily interpretable as a
surrogacy metric in gout by clinicians. Relative risk
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reduction is more familiar to clinicians than rate ratio
but ignores trial duration. Although SU<6 mg/dL is the
most common primary end point of RCTs of gout inter-
ventions, a by-arm difference in proportion achieving an
SU target may be more difﬁcult to interpret than a SU
change. In addition to gout ﬂares, the SU as a surrogate
end point for two other clinical outcomes, HRQoL and
tophus size, will also be evaluated as secondary clinical
outcomes. If the trial does not report these outcomes,
the authors will be contacted and the by-arm outcomes
requested.
A quantitative evaluation of trial-level statistical surro-
gacy using the BSES310 includes determining the slope
coefﬁcient of the surrogacy relationship, trial-level R2
(coefﬁcient of determination)22 and the surrogate
threshold effect (STE)23 24 25 and STE proportion
(STEP)8 10 of the surrogate and true-clinical-end point
relationship using data from a meta-regression of RCTs.
The STE is informative as it captures both the slope
and dispersion of the surrogate-true relationship in a
single metric.25 The STE is the SU difference needed to
predict the primary clinical end point, gout ﬂare rate
ratio, in a new trial, if only SU is measured in the new
trial. The STE is determined by comparing the differ-
ence between control and active arms SU and ﬂare rate,
respectively, as follows: (1) calculate the SU change and
gout ﬂare rate ratio based on each arm in each trial, (2)
calculate the difference between control and active arms
for SU change and gout ﬂare rate ratio, (3) regress SU
and gout ﬂare rate ratio difference values using
weighted by trial size errors-in-variables (specifying a reli-
ability coefﬁcient of 0.9) regression and by a weighted
by trial-size meta-regression (as a sensitivity analysis), (4)
calculate the 95% prediction limits of the regression and
(5) ﬁnd the SU value where the 95% prediction line
intersects with the horizontal ﬂare rate x-axis of no ﬂare
rate ratio beneﬁt (where the ﬂare rate ratio y-axis is
equal to 1.0). Similar analyses will be explored with ﬂare
rate relative risk reduction and proportion with
SU<6 mg/dL at the end of the trial. In this analysis the
interest is the SU target <6 mg/dL by-arm proportion
where the 95% prediction line intersects with the hori-
zontal ﬂare rate x-axis of no ﬂare relative risk reduction
beneﬁt (ie, where the ﬂare relative risk reduction y-axis
is equal to zero). Subsequent analyses will evaluate
HRQoL and tophus size as clinically relevant outcomes.
Where more than two arms from a single trial are
present, the by-arm comparisons are down-weighted fol-
lowing A’Hern et al26 because all within trial compari-
sons are not independent. In all trial comparisons, this
requires that a single ‘control’ comparator is deter-
mined. In trials with a true placebo, the placebo is the
control comparator. In trials without placebo, then the
control comparator is an intervention arm that best
reﬂects usual care. For example, in a ﬁve-arm trial with a
true placebo there are four comparisons, and each com-
parison is down-weighted using analytic weights.10 This
allows all arms from each trial to be evaluated in the
meta-regression but adjusted for multiple comparisons
with the control.
The primary and the secondary analyses are prespeciﬁed
as an all drug classes combined analysis. In addition to the
STE, slope, R2trial-level, and regression diagnostics, we will also
evaluate the impact of effect modiﬁers; male sex, disease
duration (<2 years, 2–10 years, more than 10 years), pres-
ence of clinical tophi (yes, no) on the SU and gout ﬂare
rate relationship. Furthermore, study design and other
trial-related methodological issues, including the effect of
differential cross-over, differential drop-out, whether trials
included mandatory ﬂare-prevention strategies such as
mandatory colchicine and non-steroidal anti-inﬂammatory
drug (NSAID), GRADE ratings20 and risk of bias tool19
ratings will also be explored.
The Scottish Intercollegiate Guidelines Network
(SIGN) checklist27 will be used to evaluate the method-
ology of longitudinal observational studies of gout.
Once these statistical results are available (1) SU
reduction and (2) SU target <6 mg/dL will be evaluated
as a surrogate end point gout using the BSES3 criteria.
DISCUSSION
It is important to emphasise that the evaluation of SU as
a surrogate end point is for the context of using SU as an
end point in clinical trials (surrogate biomarker). This is
quite different to using SU to help guide clinical
decision-making, for example treating to a speciﬁc SU
target, or to identify that the treatment is working (moni-
toring biomarker). Although the meta-regression
approach undertaken by the proposed study will help
inform clinical decision-making, the evidence needed for
treatment targets requires a different research design.
Complete application of the BSES3 framework ideally
also uses individual patient level data from multiple clin-
ical trials. Although this analysis is planned, it is contin-
gent on agreement of relevant pharmaceutical
companies to share their data and is therefore not a
formal part of this protocol.
Observational studies will be included in the search
strategy, but will be reported separately as a narrative
review in light of the inherent risk of bias in non-
randomised and uncontrolled observational study
designs.
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